About
Key Highlights
- Among non-U.S.–born persons, less than 2% of cases had multidrug-resistant (MDR) TB disease. Among 233 non-U.S.–born persons with previous TB, 19% had isoniazid-resistant TB and 7% had MDR TB.
- Among 5,405 non-U.S.–born persons with no previous TB, 10% had isoniazid-resistant TB and 1% had MDR TB.
Data Table
Tuberculosis Cases and Percentages Among Non-U.S.–Born Persons1 by Drug Resistance2 and History of Previous TB Disease: United States, 1993–2024
| Year | Total cases3 | Isoniazid (INH)-resistant4 | Multidrug-resistant (MDR)5 | Previous TB | No previous TB | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total cases | INH-resistant | MDR | Total cases | INH-resistant | MDR | ||||||||||
| No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | ||||
| 2024 | 5,929 | 585 | (9.9) | 101 | (1.7) | 233 | 45 | (19.3) | 16 | (6.9) | 5,405 | 518 | (9.6) | 78 | (1.4) |
| 2023 | 5,709 | 537 | (9.4) | 99 | (1.7) | 194 | 27 | (13.9) | 16 | (8.2) | 5,187 | 481 | (9.3) | 78 | (1.5) |
| 2022 | 4,899 | 472 | (9.6) | 84 | (1.7) | 221 | 42 | (19.0) | 20 | (9.0) | 4,576 | 416 | (9.1) | 63 | (1.4) |
| 2021 | 4,505 | 456 | (10.1) | 75 | (1.7) | 185 | 31 | (16.8) | 10 | (5.4) | 4,278 | 419 | (9.8) | 63 | (1.5) |
| 2020 | 4,061 | 385 | (9.5) | 53 | (1.3) | 167 | 26 | (15.6) | 8 | (4.8) | 3,864 | 357 | (9.2) | 45 | (1.2) |
| 2019 | 4,972 | 531 | (10.7) | 79 | (1.6) | 211 | 33 | (15.6) | 14 | (6.6) | 4,733 | 496 | (10.5) | 65 | (1.4) |
| 2018 | 4,952 | 530 | (10.7) | 91 | (1.8) | 235 | 46 | (19.6) | 17 | (7.2) | 4,684 | 481 | (10.3) | 73 | (1.6) |
| 2017 | 4,981 | 525 | (10.5) | 110 | (2.2) | 221 | 52 | (23.5) | 25 | (11.3) | 4,736 | 469 | (9.9) | 84 | (1.8) |
| 2016 | 4,899 | 521 | (10.6) | 89 | (1.8) | 219 | 50 | (22.8) | 18 | (8.2) | 4,662 | 468 | (10.0) | 70 | (1.5) |
| 2015 | 5,001 | 526 | (10.5) | 75 | (1.5) | 218 | 44 | (20.2) | 13 | (6.0) | 4,763 | 482 | (10.1) | 62 | (1.3) |
| 2014 | 4,830 | 521 | (10.8) | 84 | (1.7) | 242 | 58 | (24.0) | 24 | (9.9) | 4,559 | 459 | (10.1) | 60 | (1.3) |
| 2013 | 4,813 | 532 | (11.1) | 87 | (1.8) | 203 | 40 | (19.7) | 10 | (4.9) | 4,578 | 490 | (10.7) | 76 | (1.7) |
| 2012 | 4,824 | 533 | (11.0) | 76 | (1.6) | 229 | 47 | (20.5) | 12 | (5.2) | 4,567 | 486 | (10.6) | 64 | (1.4) |
| 2011 | 5,084 | 571 | (11.2) | 110 | (2.2) | 208 | 50 | (24.0) | 26 | (12.5) | 4,852 | 515 | (10.6) | 84 | (1.7) |
| 2010 | 5,191 | 519 | (10.0) | 89 | (1.7) | 231 | 50 | (21.6) | 14 | (6.1) | 4,906 | 464 | (9.5) | 73 | (1.5) |
| 2009 | 5,432 | 561 | (10.3) | 103 | (1.9) | 225 | 46 | (20.4) | 18 | (8.0) | 5,143 | 508 | (9.9) | 84 | (1.6) |
| 2008 | 5,965 | 632 | (10.6) | 83 | (1.4) | 259 | 44 | (17.0) | 16 | (6.2) | 5,654 | 585 | (10.3) | 67 | (1.2) |
| 2007 | 6,107 | 613 | (10.0) | 102 | (1.7) | 288 | 57 | (19.8) | 16 | (5.6) | 5,757 | 548 | (9.5) | 83 | (1.4) |
| 2006 | 6,107 | 659 | (10.8) | 104 | (1.7) | 289 | 57 | (19.7) | 19 | (6.6) | 5,771 | 597 | (10.3) | 84 | (1.5) |
| 2005 | 5,962 | 625 | (10.5) | 101 | (1.7) | 267 | 52 | (19.5) | 21 | (7.9) | 5,653 | 567 | (10.0) | 77 | (1.4) |
| 2004 | 6,111 | 643 | (10.5) | 98 | (1.6) | 263 | 49 | (18.6) | 23 | (8.7) | 5,793 | 588 | (10.2) | 74 | (1.3) |
| 2003 | 6,202 | 669 | (10.8) | 92 | (1.5) | 271 | 49 | (18.1) | 19 | (7.0) | 5,880 | 607 | (10.3) | 70 | (1.2) |
| 2002 | 6,065 | 682 | (11.2) | 120 | (2.0) | 265 | 57 | (21.5) | 23 | (8.7) | 5,729 | 622 | (10.9) | 97 | (1.7) |
| 2001 | 6,283 | 625 | (9.9) | 110 | (1.8) | 302 | 59 | (19.5) | 26 | (8.6) | 5,915 | 559 | (9.5) | 81 | (1.4) |
| 2000 | 5,976 | 684 | (11.4) | 104 | (1.7) | 272 | 62 | (22.8) | 24 | (8.8) | 5,668 | 617 | (10.9) | 80 | (1.4) |
| 1999 | 5,946 | 677 | (11.4) | 111 | (1.9) | 284 | 55 | (19.4) | 22 | (7.7) | 5,600 | 614 | (11.0) | 88 | (1.6) |
| 1998 | 6,003 | 711 | (11.8) | 93 | (1.5) | 262 | 60 | (22.9) | 17 | (6.5) | 5,697 | 644 | (11.3) | 76 | (1.3) |
| 1997 | 6,036 | 719 | (11.9) | 111 | (1.8) | 286 | 74 | (25.9) | 32 | (11.2) | 5,710 | 640 | (11.2) | 79 | (1.4) |
| 1996 | 6,026 | 717 | (11.9) | 124 | (2.1) | 304 | 74 | (24.3) | 22 | (7.2) | 5,684 | 637 | (11.2) | 102 | (1.8) |
| 1995 | 6,065 | 713 | (11.8) | 128 | (2.1) | 364 | 91 | (25.0) | 42 | (11.5) | 5,660 | 618 | (10.9) | 85 | (1.5) |
| 1994 | 5,685 | 732 | (12.9) | 149 | (2.6) | 338 | 93 | (27.5) | 38 | (11.2) | 5,297 | 634 | (12.0) | 110 | (2.1) |
| 1993 | 5,014 | 643 | (12.8) | 149 | (3.0) | 301 | 75 | (24.9) | 46 | (15.3) | 4,672 | 565 | (12.1) | 103 | (2.2) |
1Persons born in the United States, certain U.S. territories, or elsewhere to at least one U.S. citizen parent are categorized as U.S.-born. All other persons are categorized as non-U.S.–born.
2Starting in 2023, information on drug resistance included results of molecular drug susceptibility testing in addition to growth-based susceptibility testing for isoniazid and rifampin. An isolate is considered resistant to isoniazid or rifampin if either the growth-based test or molecular test detects resistance.
3Persons with susceptibility results for at least isoniazid and rifampin. Includes persons with unknown history of previous TB disease.
4Resistance to at least isoniazid.
5Resistance to at least isoniazid and rifampin.
Notes
Data for all years are updated through July 10, 2025.